Everest Medicines Secures Exclusive License to Commercialize MT1013 in Greater China and Asia
Everest Medicines Limited has secured an exclusive license from Shaanxi Micot Pharmaceutical Technology Co., Ltd. to commercialize MT1013 in Greater China and other Asian markets. MT1013 is a first-in-class dual-targeting receptor agonist polypeptide aimed at treating secondary hyperparathyroidism, with potential expansion into chronic kidney disease-mineral and bone disorder and osteoporosis. This collaboration will enhance Everest Medicines’ nephrology portfolio.
